54 results
8-K
WINT
Windtree Therapeutics Inc
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
discounts and commissions, incident to the Company’s obligations under the Registration Rights Agreement.
The foregoing is only a summary of the material
8-K
EX-1.1
WINT
Windtree Therapeutics Inc
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
statement became effective.
5. Payment of Expenses. The Company agrees to pay the costs and expenses incident to the performance of its obligations under … Section 4(n)), which shall be paid upon the Execution Time; and (xi) all other costs and expenses incident to the performance by the Company of its
424B5
WINT
Windtree Therapeutics Inc
9 Nov 23
Prospectus supplement for primary offering
4:11pm
. We are required to pay certain fees and expenses incurred by us incident to the registration of the securities held by the selling stockholders. We
8-K
EX-1.1
WINT
Windtree Therapeutics Inc
24 Apr 23
Entry into a Material Definitive Agreement
4:40pm
at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited to: (a) all
8-K
EX-1.1
gnf2ucotwbx238l
24 Mar 21
Entry into a Material Definitive Agreement
5:20pm
8-K
EX-10.1
5driula0htmc5cx0nt
9 Dec 19
Windtree Therapeutics Completes $26.4 Million Private Placement
5:09pm
8-K
EX-10.2
gv9mrkjl4 4l4f
9 Dec 19
Windtree Therapeutics Completes $26.4 Million Private Placement
5:09pm
8-K
EX-10.4
xmyfar
21 Dec 18
Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company Targeting Cardiovascular and Respiratory Diseases
5:28pm
8-K
EX-10.3
yyebdhanhvjcs 84
21 Dec 18
Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company Targeting Cardiovascular and Respiratory Diseases
5:28pm
8-K
EX-10.1
4l2jnqucbatf2
21 Dec 18
Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company Targeting Cardiovascular and Respiratory Diseases
5:28pm
8-K
EX-3.2
ki6pjy
18 Apr 16
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
EX-1.1
j4o q9zeh
31 Oct 13
Discovery Labs Prices $50 Million Public Offering of
12:00am